Botanix Pharmaceuticals Limited · ASX:BOT
Botanix Pharmaceuticals — Shareholder Meeting (October 2019)
23 slides from Botanix Pharmaceuticals's shareholder meeting presentation, Oct 28, 2019
Slide 1: Botanix 2019 Annual General Meeting Presentation (ASX Media Release)
ASX/Media Release 28 October 2019 For personal use only Botanix Pharmaceuticals 2019 Annual General Meeting Presentation Philadelphia PA and Sydney Australia, 28 October 2019: Clinical stage cannabinoid company Botanix Pharmaceuticals Limited (ASX:BOT, “Botanix” or “the Company”) is pleased to relea
Slide 2: Cautionary Note on Forward-Looking Statements
Cautionary Note on Forward-Looking Statements For personal use only Any statements in this press release about future expectations, plans and prospects for the Company, the Company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate, ”expect,”
Slide 3: Botanix Pharmaceuticals AGM October 2019
For personal use only Botanix Pharmaceuticals AGM October 2019
Slide 4: Botanix overview
Botanix overview Botanix is a clinical stage synthetic cannabinoid company focused on developing topical products for the treatment of skin diseases For personal use only One of the world’s most advanced pharmaceutically focused synthetic Pharma focused cannabinoid (CBD) companies Proprietary Permet
Slide 5: Advanced dermatology pipeline with near term milestones
Advanced dermatology pipeline with near term milestones Combination of clinical, safety and mechanism of action data from recent Botanix studies provide support ongoing clinical programs including near term completion of Phase 2 AD study For personal use only Product Indication Ph 1 Ph 1b Ph 2 Ph 3
Slide 6: Topical CBD is well suited to treat skin disease
Topical CBD is a well suited to treat skin disease Botanix has generated strong scientific support for synthetic CBD’s anti-inflammatory and immune modulation mechanisms of actions, combined with newly identified antimicrobial effects For personal use only CBD anti-inflammatory / immune modulating e
Slide 7: BTX 1503 - acne
For personal use only BTX 1503 - acne Botanix Overview – October 2019 www.botanixpharma.com 5
Slide 8: BTX 1503: Phase 2 top line data
Acne BTX 1503: Phase 2 top line data Solid efficacy and safety results show BTX 1503 5% once-a-day dose is the best treatment to take forward into Phase 3 studies For personal use only All doses of BTX 1503 were very safe - no serious adverse events or treatment BTX 1503 is safe and related disconti
Slide 9: BTX 1503: CBD mechanism of action – supported by data
Acne BTX 1503: CBD mechanism of action – supported by data BTX 1503 is a safe and well tolerated topical acne treatment that potentially addresses all the key causes of acne For personal use only Inflammatory Lesion 1 CBD normalises sebum 3 CBD exerts a broad anti- production inflammatory effect • I
Slide 10: Key takeaways and next steps
Acne Key takeaways and next steps Overall efficacy and safety and statistical significance of Australian data provide confidence to proceed with end of Phase 2 FDA meeting and preparation for Phase 3 clinical studies For personal use only Outcomes support and expand on Phase 1b results • Overall saf
Slide 11: BTX 1204 – atopic dermatitis
For personal use only BTX 1204 – atopic dermatitis Botanix Overview – October 2019 www.botanixpharma.com 9
Slide 12: BTX 1204: CBD mechanism of action in atopic dermatitis
Atopic dermatitis BTX 1204: CBD mechanism of action in atopic dermatitis Ideal therapy that addresses multiple factors of disease pathology For personal use only 1 CBD inhibits itch 2 CBD repairs barrier dysfunction Suppresses itch by interacting with Inhibits p38 MAP Kinase activation and VR/TRPV-1
Slide 13: Atopic dermatitis market projected to be ~US$25B in 2027
Atopic dermatitis Atopic dermatitis market projected to be ~US$25B in 2027 BTX 1204 addresses the need for a safe, non steroid topical option for chronic use with multiple mechanisms of action including anti-inflammatory, anti-microbial and immune modulating For personal use only One of the most com
Slide 14: BTX 1204 Phase 1b study results support efficacy and safety potential
Atopic dermatitis BTX 1204 Phase 1b study results support efficacy and safety potential BTX 1204 was twice as effective as vehicle (with efficacy still increasing) and displayed a substantial improvement in the key signs of atopic dermatitis1 For personal use only Treatment success (%)2 40% Efficacy
Slide 15: BTX 1204: atopic dermatitis – Phase 2 recruiting
Atopic dermatitis BTX 1204: atopic dermatitis – Phase 2 recruiting 12-week randomised, double-blind, vehicle-controlled study to evaluate the safety and efficacy of BTX 1204 in patients with moderate atopic dermatitis For personal use only Study Design Endpoints • 2 dose groups: ~200 subjects • Prim
Slide 16: Additional Pipeline programs
For personal use only Additional Pipeline programs 1. BTX 1702: rosacea 2. BTX 1801: antimicrobial Botanix Overview – October 2019 www.botanixpharma.com 14
Slide 17: BTX 1702: impact of papulopustular rosacea
Rosacea BTX 1702: impact of papulopustular rosacea Papulopustular rosacea is a chronic skin disease characterised by redness (inflammation) and acne- like break-outs1 For personal use only Affects ~16m Americans3 Survey of 1,675 Literature review of 17 studies • ~5.5% of the adult population is affe
Slide 18: BTX 1702 study design
Rosacea BTX 1702 study 6 week randomised, double-blind, vehicle-controlled study to evaluate the safety and tolerability of BTX 1702 in patients with papulopustular rosacea For personal use only Study Design Endpoints • 2 dose groups: ~36 patients • Primary endpoint - BTX 1702 twice daily: 24 patien
Slide 19: BTX 1801 - antimicrobial
Antimicrobial BTX 1801 - antimicrobial Cannabidiol is a powerful new antibiotic that is effective in tests against Staphylococcus aureus (“staph’”) and methicillin resistant Staphylococcus aureus (“MRSA or golden staph”) 1 For personal use only Antibiotic S. aureus all isolates (µg/mL) MRSA1 (µg/mL)
Slide 20: Near term milestones
Near term milestones Key near term milestones combine clinical and other endpoints and provide solid news flow through 2Q CY 2020 For personal use only Event Timing BTX 1702 rosacea study kickoff 4Q CY2019 BTX 1801 antimicrobial study kickoff 4Q CY2019 BTX 1204 atopic dermatitis study data 1Q CY2020
Slide 21: Inflammation + bacterial infection are important to most skin diseases
Inflammation + bacterial infection are important to most skin diseases1 Newly announced data provide scientific support for synthetic CBD’s mechanism of action (MOA), which is highly relevant to all Botanix pipeline products For personal use only Acne Atopic dermatitis Relevance CBD mechanism of act
Slide 22: Disclaimer
Disclaimer For personal use only Any statements in this press release about future expectations, plans and prospects for the Company, the Company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate, ”expect,” “intend,” “may,” “plan,” “predict,”
Slide 23: Contact us
For personal use only Contact us Ric Peterson Botanix Pharmaceuticals Chief Financial Officer investors@botanixpharma.com Visit us www.botanixpharma.com Follow us on social media Botanix Pharmaceuticals Limited (ASX:BOT) www.botanixpharma.com 21
Botanix Pharmaceuticals — Shareholder Meeting (October 2019) on 6ix